By Fineline Cube 
China-based Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557) announced that it has received approval from the National Medical Products Administration (NMPA) to initiate a clinical study assessing its Category 1 investigational chemical drug KYS2301 gel in atopic dermatitis (AD).
KYS2301: First CCR8-Targeted Peptide Inhibitor
KYS2301 is a novel chemokine receptor 8 (CCR8)-specific inhibitor independently developed by Kanion Pharma. It represents the world’s first peptide inhibitor targeting CCR8, available in formulations at 1%, 3%, and 5% concentrations. Preclinical studies demonstrated high affinity for the CCR8 target, significant therapeutic efficacy in AD when applied topically, and an excellent safety profile. Toxicology and pharmacokinetic data showed low systemic exposure and good tolerance with repeated application.-Fineline Info & Tech